IV Erwinaze: Phase I started

Jazz began an open-label, North American Phase I trial to evaluate 25,000 IU/m 2 IV Erwinaze thrice weekly in up to 25 ALL patients ages 1-30 years. A muscular injection formulation of Erwinaze is approved in the U.S., Canada, U.K. and several EU member states to treat ALL in patients with hypersensitivity to E. coli-derived asparaginase and -pegaspargase chemotherapy drugs. ...